Quanterix Corp (QTRX)

May 23, 2025, 2:21 PM EDT - 13 days ago

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

AKYA

May 12, 2025, 11:19 PM EDT - 24 days ago

Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 24 days ago

Quanterix Releases Financial Results for the First Quarter of 2025

May 7, 2025, 3:46 PM EDT - 4 weeks ago

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

AKYA

May 5, 2025, 7:00 AM EDT - 4 weeks ago

Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

Apr 30, 2025, 8:00 AM EDT - 5 weeks ago

Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

AKYA

Apr 29, 2025, 7:00 AM EDT - 5 weeks ago

Quanterix and Akoya Biosciences Announce Amended Merger Agreement

AKYA

Apr 17, 2025, 8:30 AM EDT - 7 weeks ago

Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders

Apr 14, 2025, 8:00 AM EDT - 7 weeks ago

Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences

AKYA

Apr 7, 2025, 8:15 AM EDT - 2 months ago

Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya

AKYA

Apr 1, 2025, 1:00 AM EDT - 2 months ago

Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit

Mar 24, 2025, 8:00 AM EDT - 2 months ago

Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences

AKYA

Mar 17, 2025, 7:19 PM EDT - 2 months ago

Quanterix Corporation (QTRX) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:01 PM EDT - 2 months ago

Quanterix Releases Financial Results for the Fourth Quarter of 2024

Mar 17, 2025, 4:00 PM EDT - 2 months ago

Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call

AKYA

Mar 13, 2025, 1:00 PM EDT - 3 months ago

Quanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

Mar 11, 2025, 8:00 AM EDT - 3 months ago

Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix's Proposed Merger with Akoya Biosciences

AKYA

Mar 3, 2025, 8:00 AM EST - 3 months ago

Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

Mar 3, 2025, 6:00 AM EST - 3 months ago

Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition

Mar 2, 2025, 11:00 AM EST - 3 months ago

The Schall Law Firm Invites Shareholders With Losses In Quanterix Corporation To Join A Securities Fraud Investigation

Feb 19, 2025, 8:30 AM EST - 3 months ago

Neurogen Biomarking Announces Global Agreement with Quanterix for Use of Blood Biomarker Assay in its Patient-Initiated Blood Test to Support Early Detection of Dementia and Mild Cognitive Impairment Due to Alzheimer's Disease

Feb 18, 2025, 3:40 PM EST - 3 months ago

Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences

AKYA

Feb 14, 2025, 5:48 PM EST - 3 months ago

Quanterix Corporation Announcement: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Feb 5, 2025, 3:43 PM EST - 4 months ago

Quanterix Investor News: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Feb 1, 2025, 11:00 AM EST - 4 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Quanterix Corporation For Securities Fraud

Jan 28, 2025, 9:00 PM EST - 4 months ago

Bragar Eagel & Squire, P.C. Is Investigating Quanterix and TransMedics and Encourages Investors to Contact the Firm

TMDX

Jan 28, 2025, 11:00 AM EST - 4 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Quanterix Corporation For Securities Fraud

Jan 14, 2025, 7:00 AM EST - 5 months ago

Quanterix Provides Update on Financial Performance

Jan 10, 2025, 7:00 AM EST - 5 months ago

Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

AKYA

Jan 6, 2025, 9:30 AM EST - 5 months ago

David R. Walt Receives National Medal of Technology and Innovation

Jan 2, 2025, 4:26 PM EST - 5 months ago

Quanterix to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 28, 2024, 1:15 PM EST - 5 months ago

The Schall Law Firm Invites Shareholder Contributions To An Inquiry Into Quanterix Corporation For Securities Fraud

Dec 23, 2024, 10:45 AM EST - 5 months ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Quanterix Corporation For Securities Fraud

Dec 20, 2024, 2:00 PM EST - 5 months ago

The Schall Law Firm Urges Stockholder Participation In An Inquiry Into Quanterix Corporation For Securities Fraud

Dec 18, 2024, 10:45 AM EST - 6 months ago

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Quanterix Corporation For Securities Fraud

Dec 17, 2024, 6:59 AM EST - 6 months ago

Quanterix Expands Capabilities with Strategic Acquisition of EMISSION

Dec 16, 2024, 10:45 AM EST - 6 months ago

The Schall Law Firm Invites Shareholder Contributions To An Inquiry Into Quanterix Corporation's Possible Securities Fraud

Dec 14, 2024, 5:15 PM EST - 6 months ago

The Schall Law Firm Invites Shareholder Contributions To An Inquiry Into Quanterix Corporation For Possible Securities Fraud

Dec 12, 2024, 1:15 PM EST - 6 months ago

The Schall Law Firm Invites Stockholder Participation In An Inquiry Into Quanterix Corporation For Possible Securities Fraud

Dec 9, 2024, 5:00 PM EST - 6 months ago

Quanterix Corporation Is Being Investigated For Violating Securities Laws And Impacted Investors Are Urged To Contact The Schall Law Firm